Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26987866 | 1.00 | VNN1 (0.43) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20484883 | 0.88 | VNN1 (0.35) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21682777 | 0.87 | VNN1 (0.43) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21359037 | 0.85 | VNN1 (0.34) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15716997 | 0.82 | USP2 (0.36) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13223517 | 0.82 | VNN1 (0.40) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21834363 | 0.81 | EPHX1 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL26988027 | 0.81 | VNN1 (0.33) | VNN1CYP3A4KMT2ACYP2D6EPHX2 | |
| SCHEMBL26989271 | 0.81 | VNN1 (0.33) | VNN1CYP3A4KMT2ACYP2D6EPHX2 | |
| SCHEMBL18598805 | 0.80 | VNN1 (0.39) | VNN1NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024009191-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-2920183-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-2261210-B1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | MSD KK (JP) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| US-8367698-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | NAGASE TSUYOSHI (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8188280-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | MSD K.K. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2261210-A1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | VNN1 4687/4885NPC1 3613/4885RAB9A 965/4885 |
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | VNN1 4602/4885NPC1 129/4885RAB9A 1472/4885 |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | VNN1 4602/4885NPC1 129/4885RAB9A 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.